Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts ARQT Hot Sheet
Join SI Premium – FREE
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.09), $0.19 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $71.3 million versus the consensus estimate of $54.72 million.
For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Arcutis presents Zoryve and corticosteroid data at dermatology meetings
- Jet fuel prices near $5 per gallon in New York and Los Angeles
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
